<DOC>
	<DOCNO>NCT01323998</DOCNO>
	<brief_summary>This retrospective study aim assess treatment pattern within 1 year initiate BPH treatment , include 5-alpha-reductase inhibitor ( 5ARI ) monotherapy , alpha-blocker ( AB ) monotherapy , early combination therapy , delay combination therapy . The MarketScan database utilized study ( 2000-2008 )</brief_summary>
	<brief_title>Benign Prostatic Hypertrophy Treatment Patterns &amp; Outcomes : Marketscan</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<criteria>Male age 50 year older diagnostic claim BPH least one prescription claim 5ARI AB enrollment period continuous eligibility 6 month prior 12 month index prescription date diagnosis prostate bladder cancer study period prostaterelated surgical procedure within 1 month index prescription date prescription claim finasteride 1 mg male pattern baldness study period</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>enlarge prostate</keyword>
	<keyword>Benign prostatic hyperplasia</keyword>
	<keyword>alpha-blocker</keyword>
	<keyword>5-alpha-reductase inhibitor</keyword>
</DOC>